dose response curves for capivasertib  (MedChemExpress)

Journal: Cell Reports Methods

Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss

doi: 10.1016/j.crmeth.2026.101370

Figure Lengend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .

Article Snippet: Dose-response curves for capivasertib (MedChemExpress # HY-15431), the PDPK1/AKT/FLT dual pathway inhibitor (DPI) (SantaCruz Biotechnology #CAS 331253-86-2) and tenovin-6 (T6) (MedChemExpress #1011301-29-3) were performed on in vivo and in vitro organoids and tumoroids.

Techniques: In Vivo, In Vitro, Concentration Assay

Journal: bioRxiv

Article Title: ButterflyVI: enabling high-throughput variant interpretation and biomarker discovery with functional genomics

doi: 10.64898/2026.01.20.700339

Figure Lengend Snippet: A-B , Dose response curves to control DMSO ( A ) or Nutlin-3a ( B ) treatment on RT-4 and KU-19-19 models. Cellular viability is expressed as a percentage relative to the untreated control. Each data point represents a single experimental data point (replicate). The blue line shows the fit of the four-parameter log-logistic model. The light blue shaded band represents the 95% confidence interval for the model. The vertical red dashed line indicates the calculated IC50, and the pink shaded band represents the 95% confidence interval for the IC50 value. The specific IC50 value and its confidence interval are indicated on the graph. C , Relative expression of GAPDH in cells transfected with control siRNA (siCtrl), GAPDH siRNA (siGAPDH), or RPL5 siRNA (siRPL5). Data are presented as the mean ± standard error of the mean (SEM). Differences between groups were evaluated using an unpaired Student’s t-test. The level of statistical significance is indicated by asterisks: ns, not significant (P > 0.05); ** P ≤ 0.01; * P ≤ 0.05.

Article Snippet: Prior to the main experiment, a Nutlin-3a (Selleckchem, S8059) dose–response assay was performed to determine the sensitivity of KU-19-19 and RT-4 cells, using concentrations based on IC50 values from the Genomics of Drug Sensitivity in Cancer (GDSC) database for KU-19-19 (2.51 μg/mL ≈ 12.18 μM) and RT-4 (2.50 μg/mL ≈ 12.18 μM), including doses below (0.15, 0.3, 0.6, 1.2, 3, 6, and 9 μM) and above (25 and 50 μM) the IC50.

Techniques: Control, Expressing, Transfection